Angiotensin Inhibition, TGF-β and EMT in Cancer

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Angiotensin inhibitors are established treatments for cardiovascular and renal diseases, possessing antihypertensive and antifibrotic properties.
• These drugs demonstrate antifibrotic effects in cancer by decreasing collagen and hyaluronan in the tumor stroma, which improves drug delivery.
• Angiotensin II signaling disrupts the secretion of TGF-β (transforming growth factor-beta), a cytokine implicated in cancer progression.

Purpose of the Study:

• To explore the antifibrotic mechanisms of angiotensin inhibitors in cancer.
• To investigate the role of TGF-β signaling in cancer malignancy and metastasis.
• To understand the impact of TGF-β on cancer cell behavior and epithelial-mesenchymal transition (EMT).

Main Methods:

• Review of existing literature on angiotensin inhibitors, TGF-β signaling, and cancer biology.
• Analysis of the molecular pathways involved in TGF-β-induced desmoplasia and EMT.
• Examination of the interplay between angiotensin II signaling and TGF-β secretion.

Main Results:

• Angiotensin inhibitors reduce tumor stroma deposition of collagen and hyaluronan, thereby enhancing drug penetration.
• TGF-β, a malignancy driver, stimulates matrix production in cancer-associated fibroblasts, promoting desmoplasia.
• TGF-β signaling, through SMAD-dependent and independent pathways, influences cancer cell behavior and induces EMT, a hallmark of metastasis.

Conclusions:

• Angiotensin inhibitors offer a dual benefit in cancer therapy by reducing tumor fibrosis and potentially modulating TGF-β signaling.
• Targeting TGF-β signaling represents a promising strategy for cancer drug development due to its role in malignancy and metastasis.
• Understanding the complex regulation of EMT is crucial for developing effective anti-metastatic therapies.